May 30 (Reuters) - Resverlogix Corp RVX.TO
* Resverlogix receives approval from health canada to proceed with fabry disease clinical trial with lead compound apabetalone
* Resverlogix- received approval from health canada, therapeutic products directorate, to proceed with clinical trial with lead compound apabetalone in patients with fabry disease Source text for Eikon: ID:nCNWCcqNma Further company coverage: RVX.TO